Edgewood Management
KIN

Edgewood Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Edgewood Management’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30,000
Closed -$149K – 85
2021
Q1 		$149K Hold
30,000
– – ﹤0.01% 82
2020
Q4 		$129K Hold
30,000
– – ﹤0.01% 78
2020
Q3 		$129K Hold
30,000
– – ﹤0.01% 76
2020
Q2 		$135K Hold
30,000
– – ﹤0.01% 75
2020
Q1 		$120K Buy
30,000
+5,000
+20% +$42.5K ﹤0.01% 77
2019
Q4 		$212K Buy
+25,000
New +$195K ﹤0.01% 80

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Edgewood Management's KIN Position: Q2 2021 in Review

Edgewood Management sold out of Kindred Biosciences, Inc. (KIN) in Q2 2021, closing a stake of 30,000 shares — an estimated $149K sold.

Edgewood Management first reported a position in KIN in Q4 2019 and held it in 6 quarters. The position peaked at $212K in Q4 2019. 87 funds tracked by Wall St. Rank hold KIN as of Q2 2021.

  • Edgewood Management reported no remaining Kindred Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • Edgewood Management sold 30,000 Kindred Biosciences, Inc. shares in Q2 2021, an estimated $149K.
  • Edgewood Management first reported a position in Kindred Biosciences, Inc. in Q4 2019 and held it in 6 quarters.
  • Edgewood Management's Kindred Biosciences, Inc. position peaked at $212K in Q4 2019.
  • 87 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2021.

Based on Edgewood Management's 13F filing for Q2 2021, filed 12 Aug 2021.